1. Home
  2. COCH vs SER Comparison

COCH vs SER Comparison

Compare COCH & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

N/A

Current Price

$0.70

Market Cap

51.0M

Sector

Finance

ML Signal

N/A

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

N/A

Current Price

$2.11

Market Cap

56.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
COCH
SER
Founded
1995
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
56.4M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
COCH
SER
Price
$0.70
$2.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$6.00
★ $15.00
AVG Volume (30 Days)
50.5K
★ 53.1K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 17.45
N/A
EPS
★ N/A
N/A
Revenue
★ $241,000.00
$130,000.00
Revenue This Year
$1.58
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
7.11
★ 132.14
52 Week Low
$0.36
$1.22
52 Week High
$1.89
$5.83

Technical Indicators

Market Signals
Indicator
COCH
SER
Relative Strength Index (RSI) 46.24 38.92
Support Level $0.63 $1.69
Resistance Level $0.74 $2.29
Average True Range (ATR) 0.03 0.23
MACD -0.00 -0.04
Stochastic Oscillator 32.11 11.54

Price Performance

Historical Comparison
COCH
SER

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: